• Phase
  • This is a Phase 3b, multicenter, open-label, randomized, controlled study to evaluate efficacy, safety and population pharmacokinetics of sapropterin dihydrochloride (KuvanĀ®) in less than 4 year-old infants and children with phenylketonuria (PKU). (clinicaltrials.gov)
  • study
  • This study, PKU-016, will be conducted in PKU patients to evaluate the therapeutic effects of sapropterin dihydrochloride on the symptoms of attention deficit hyperactivity disorder (ADHD), depression, and anxiety. (clinicaltrials.gov)